Sound Bioventures
Early-stage biotech VC; participated in Cytospire's £61m Series A.
Last refreshed: 13 May 2026 · Appears in 1 active topic
Timeline for Sound Bioventures
Cytospire's £61m oncology Series A oversubscribed
UK Startups and InnovationBackground
Sound Bioventures participated in Cytospire's £61m Series A in May 2026 alongside Abingworth, Servier Ventures, LifeArc Ventures, and Medical Incubator Japan. Cytospire is developing CYT X300, a pan-gamma delta T cell engager for solid tumours.
Sound Bioventures is a biotech venture firm focused on early-stage therapeutic discovery and development. It has a limited public disclosure profile; deal participation in the Cytospire round alongside established European and Japanese biotech investors suggests an institutional vehicle with biotech sector expertise. The Firm's co-investment with LifeArc Ventures and Abingworth signals a broadly UK and European-oriented mandate for this deal.
What is Sound Bioventures?
Who are the investors in Cytospire's oncology round?
What is Cytospire developing?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 13 May 2026. Editorial standards.